Wirth and Sheibenorgen hypothesise in their new paper that beta 2-adrenergic receptor dysfunction is of critical importance in the pathophysiology of ME/CFS, in causing vascular dysregulation.
While BC 007 has been found to have effect in Long Covid via eliminating functional pathogenic autoantibodies directed against the beta-1 adrenoceptor, Berlin Cures has also assessed it for neutralising GPCR autoantibodies against all of alpha-1 adrenergic receptor (α(1)-AR AAB), beta-1 adrenergic receptor (ß(1)-AR AAB), beta-2 adrenergic receptor (ß(2)-AR AAB) and endothelin-A-receptor (ETA AAB) and found BC 007 to be effective for all of these.
https://www.prnewswire.co.uk/news-r...of-bc-007-for-the-treatment-of-691428881.html
https://clinicaltrials.gov/ct2/show/NCT02955420
It has been supported by others researching dementia that BC 007 can neutralise GPCR autoantibodies against beta 1 and 2 adrenergic receptors in that condition.
https://pubmed.ncbi.nlm.nih.gov/29538413/
Wirth and Sheibenorgen hypothesise in their new paper (Pathophysiology of skeletal muscle disturbances in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome) that beta 2-adrenergic receptor dysfunction is of critical importance in the pathophysiology of ME/CFS, in causing vascular dysregulation, so BC 007 may have some potential for ME/CFS also.
https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-021-02833-2